ProQR Therapeutics N.V.

NasdaqCM PRQR

ProQR Therapeutics N.V. Net Cash Used For Investing Activities for the year ending December 31, 2023: USD 4.72 M

ProQR Therapeutics N.V. Net Cash Used For Investing Activities is USD 4.72 M for the year ending December 31, 2023, a 728.66% change year over year. Net cash used for investing activities is total cash inflows and outflows related to activities intended to generate future income and cash flows from investments.

ProQR Therapeutics N.V. Net Cash Used For Investing Activities for the year ending December 31, 2022 was USD -751.10 K, a -55.25% change year over year.
ProQR Therapeutics N.V. Net Cash Used For Investing Activities for the year ending December 31, 2021 was USD -483.80 K, a 57.14% change year over year.
ProQR Therapeutics N.V. Net Cash Used For Investing Activities for the year ending December 31, 2020 was USD -1.13 M, a -73.41% change year over year.
ProQR Therapeutics N.V. Net Cash Used For Investing Activities for the year ending December 31, 2019 was USD -650.89 K, a -82.28% change year over year.

Key data

Date	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid	Capital Expenditure

NasdaqCM: PRQR

ProQR Therapeutics N.V.

CEO	Mr. Daniel Anton de Boer
IPO Date	Sept. 18, 2014
Location	Netherlands
Headquarters	Zernikedreef 9
Employees	156
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

Key trends

Past 5 years